181 related articles for article (PubMed ID: 18189069)
21. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit.
Ghannoum MA; Chen A; Buhari M; Chandra J; Mukherjee PK; Baxa D; Golembieski A; Vazquez JA
Clin Microbiol Infect; 2009 Mar; 15(3):274-9. PubMed ID: 19210699
[TBL] [Abstract][Full Text] [Related]
22. Update on new antifungal therapy.
Juang P
AACN Adv Crit Care; 2007; 18(3):253-60; quiz 261-2. PubMed ID: 18019516
[TBL] [Abstract][Full Text] [Related]
23. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage.
Spanakis EK; Aperis G; Mylonakis E
Clin Infect Dis; 2006 Oct; 43(8):1060-8. PubMed ID: 16983621
[TBL] [Abstract][Full Text] [Related]
24. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.
Nagappan V; Deresinski S
Clin Infect Dis; 2007 Dec; 45(12):1610-7. PubMed ID: 18190324
[TBL] [Abstract][Full Text] [Related]
25. Posaconazole: clinical pharmacology and potential for management of fungal infections.
Groll AH; Walsh TJ
Expert Rev Anti Infect Ther; 2005 Aug; 3(4):467-87. PubMed ID: 16107193
[TBL] [Abstract][Full Text] [Related]
26. Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis.
Rautemaa R; Richardson M; Pfaller MA; Perheentupa J; Saxén H
Diagn Microbiol Infect Dis; 2008 Oct; 62(2):182-5. PubMed ID: 18597968
[TBL] [Abstract][Full Text] [Related]
27. Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections.
Groll AH; Walsh TJ
Mycoses; 2006; 49 Suppl 1():7-16. PubMed ID: 16961576
[TBL] [Abstract][Full Text] [Related]
28. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
[TBL] [Abstract][Full Text] [Related]
29. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis.
de Wet NT; Bester AJ; Viljoen JJ; Filho F; Suleiman JM; Ticona E; Llanos EA; Fisco C; Lau W; Buell D
Aliment Pharmacol Ther; 2005 Apr; 21(7):899-907. PubMed ID: 15801925
[TBL] [Abstract][Full Text] [Related]
30. Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin.
Santos RP; Sánchez PJ; Mejias A; Benjamin DK; Walsh TJ; Patel S; Jafri HS
Pediatr Infect Dis J; 2007 Apr; 26(4):364-6. PubMed ID: 17414408
[TBL] [Abstract][Full Text] [Related]
31. Posaconazole: when and how? The clinician's view.
Katragkou A; Tsikopoulou F; Roilides E; Zaoutis TE
Mycoses; 2012 Mar; 55(2):110-22. PubMed ID: 21762211
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the Sensititre Yeast One microdilution method for susceptibility testing of Candida species to anidulafungin, caspofungin, and micafungin.
García-Agudo L; García-Martos P; Martos-Cañadas J; Aznar-Marín P; Marín-Casanova P; Rodríguez-Iglesias M
Rev Esp Quimioter; 2012 Dec; 25(4):256-60. PubMed ID: 23303256
[TBL] [Abstract][Full Text] [Related]
33. Synergistic effect of anidulafungin combined with posaconazole in experimental aspergillosis.
Martin-Vicente A; Capilla J; Guarro J
Med Mycol; 2017 Jun; 55(4):457-460. PubMed ID: 27760829
[TBL] [Abstract][Full Text] [Related]
34. Micafungin: a new echinocandin.
Chandrasekar PH; Sobel JD
Clin Infect Dis; 2006 Apr; 42(8):1171-8. PubMed ID: 16575738
[TBL] [Abstract][Full Text] [Related]
35. A clinical review of echinocandins in pediatric patients.
VandenBussche HL; Van Loo DA
Ann Pharmacother; 2010 Jan; 44(1):166-77. PubMed ID: 20009006
[TBL] [Abstract][Full Text] [Related]
36. Micafungin plus fluconazole in an infected knee with retained hardware due to Candida albicans.
Bland CM; Thomas S
Ann Pharmacother; 2009 Mar; 43(3):528-31. PubMed ID: 19261955
[TBL] [Abstract][Full Text] [Related]
37. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani.
Heyn K; Tredup A; Salvenmoser S; Müller FM
Antimicrob Agents Chemother; 2005 Dec; 49(12):5157-9. PubMed ID: 16304192
[TBL] [Abstract][Full Text] [Related]
38. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.
Walsh TJ; Raad I; Patterson TF; Chandrasekar P; Donowitz GR; Graybill R; Greene RE; Hachem R; Hadley S; Herbrecht R; Langston A; Louie A; Ribaud P; Segal BH; Stevens DA; van Burik JA; White CS; Corcoran G; Gogate J; Krishna G; Pedicone L; Hardalo C; Perfect JR
Clin Infect Dis; 2007 Jan; 44(1):2-12. PubMed ID: 17143808
[TBL] [Abstract][Full Text] [Related]
39. Combination echinocandin-polyene treatment of murine mucormycosis.
Ibrahim AS; Gebremariam T; Fu Y; Edwards JE; Spellberg B
Antimicrob Agents Chemother; 2008 Apr; 52(4):1556-8. PubMed ID: 18212099
[TBL] [Abstract][Full Text] [Related]
40. A multicenter, open-label study of posaconazole oral suspension in the treatment of invasive fungal infections in patients refractory to or intolerant of first-line therapy.
Huang X; Wang F; Chen Y; Liu T; Wang J; Hu J; Jie J; Chen F; Wang S; Shen Z; Yu L; Yu K; Liang Y
Future Microbiol; 2012 Feb; 7(2):201-9. PubMed ID: 22324990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
